Crucial considerations for pipelines to validate circulating biomarkers for breast cancer

Radwa Ewaisha, Chelsea D. Gawryletz, Karen Anderson

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.

Original languageEnglish (US)
Pages (from-to)201-211
Number of pages11
JournalExpert Review of Proteomics
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Biomarkers
Pipelines
Breast Neoplasms
Exosomes
Circulating Neoplastic Cells
Recurrence
Mammography
Mortality
Monitoring
Autoantibodies
Nucleic Acids
Tumors
Screening
Breast
Cells
Imaging techniques
Research
Neoplasms
Proteins

Keywords

  • autoantibodies
  • Biomarker discovery
  • breast cancer
  • early detection
  • pipeline
  • PRoBE principles
  • validation

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. / Ewaisha, Radwa; Gawryletz, Chelsea D.; Anderson, Karen.

In: Expert Review of Proteomics, Vol. 13, No. 2, 01.02.2016, p. 201-211.

Research output: Contribution to journalArticle

@article{8fc2ea739db449f7b801612ca471fb78,
title = "Crucial considerations for pipelines to validate circulating biomarkers for breast cancer",
abstract = "Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.",
keywords = "autoantibodies, Biomarker discovery, breast cancer, early detection, pipeline, PRoBE principles, validation",
author = "Radwa Ewaisha and Gawryletz, {Chelsea D.} and Karen Anderson",
year = "2016",
month = "2",
day = "1",
doi = "10.1586/14789450.2016.1132170",
language = "English (US)",
volume = "13",
pages = "201--211",
journal = "Expert Review of Proteomics",
issn = "1478-9450",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Crucial considerations for pipelines to validate circulating biomarkers for breast cancer

AU - Ewaisha, Radwa

AU - Gawryletz, Chelsea D.

AU - Anderson, Karen

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.

AB - Despite decades of progress in breast imaging, breast cancer remains the second most common cause of cancer mortality in women. The rapidly proliferative breast cancers that are associated with high relapse rates and mortality frequently present in younger women, in unscreened individuals, or in the intervals between screening mammography. Biomarkers exist for monitoring metastatic disease, such as CEA, CA27.29 and CA15-3, but there are no circulating biomarkers clinically available for early detection, prognosis, or monitoring for clinical relapse. There has been significant progress in the discovery of potential circulating biomarkers, including proteins, autoantibodies, nucleic acids, exosomes, and circulating tumor cells, but the vast majority of these biomarkers have not progressed beyond initial research discovery, and none have yet been approved for clinical use in early stage disease. Here, the authors review the crucial considerations of developing pipelines for the rapid evaluation of circulating biomarkers for breast cancer.

KW - autoantibodies

KW - Biomarker discovery

KW - breast cancer

KW - early detection

KW - pipeline

KW - PRoBE principles

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=84957437326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957437326&partnerID=8YFLogxK

U2 - 10.1586/14789450.2016.1132170

DO - 10.1586/14789450.2016.1132170

M3 - Article

VL - 13

SP - 201

EP - 211

JO - Expert Review of Proteomics

JF - Expert Review of Proteomics

SN - 1478-9450

IS - 2

ER -